Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent prior to initiation of any study mandated procedure~2. Male or female ≥ 40 and ≤ 75 years of age~3. Women of childbearing potential1 must use a reliable method of contraception~4. Clinical diagnosis of moderate to severe COPD, with an obstructive pattern on pulmonary function tests~5. Current or past smokers of ≥ 10 pack years~6. Ability to perform exercise testing without supplemental oxygen (in the best opinion of the investigator)~7. Confirmed pulmonary hypertension by right heart catheterization (RHC)~Exclusion Criteria:~1. Other causes of pulmonary hypertension than COPD~2. BMI \> 35 kg/m2~3. Conditions considered as contraindications for cardiopulmonary exercise testing (CPET) and/or inability to pedal on a cycle ergometer~4. Pregnant or nursing~5. Currently (within 30 days prior to RHC) taking specific pulmonary arterial hypertension (PAH) therapy (e.g., bosentan, ambrisentan, tadalafil, sildenafil, epoprostenol, treprostinil, iloprost, beraprost)~6. Participation in any other clinical trial, except observational, or receipt of an investigational product within 30 days prior to RHC visit~7. Known concomitant life-threatening disease with a life expectancy \< 12 months~8. Known hypersensitivity to iloprost or any of the excipients of the drug formulations

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- iloprost (Type: EXPERIMENTAL): single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
- placebo (Type: PLACEBO_COMPARATOR): matching placebo using the power disc-6 with I-neb AAD system

Based on this trial design, predict the completion outcome and termination type (if applicable).